These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12843002)

  • 1. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92.
    Harms DO; Göbel U; Spaar HJ; Graubner UB; Jorch N; Gutjahr P; Janka-Schaub GE;
    Blood; 2003 Oct; 102(8):2736-40. PubMed ID: 12843002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
    Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
    Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
    Erb N; Harms DO; Janka-Schaub G
    Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?
    Lennard L; Davies HA; Lilleyman JS
    Br J Cancer; 1993 Jul; 68(1):186-90. PubMed ID: 8318412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: A protocol for systematic review and meta-analysis.
    Chen L; Yan HX; Liu XW; Chen WX
    Medicine (Baltimore); 2020 May; 99(18):e20082. PubMed ID: 32358392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.
    Vora A; Mitchell CD; Lennard L; Eden TO; Kinsey SE; Lilleyman J; Richards SM; ;
    Lancet; 2006 Oct; 368(9544):1339-48. PubMed ID: 17046466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
    Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
    Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy.
    Broxson EH; Dole M; Wong R; Laya BF; Stork L
    Pediatr Blood Cancer; 2005 Mar; 44(3):226-31. PubMed ID: 15503293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress of Research on 6-Thioguanine versus 6-Mercaptopurine in childhood ALL].
    Hou YJ; Zhao L; Liu XX; Ma YY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):622-6. PubMed ID: 27151041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.
    Landier W; Hageman L; Chen Y; Kornegay N; Evans WE; Bostrom BC; Casillas J; Dickens DS; Angiolillo AL; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Relling MV; Wong FL; Bhatia S
    J Clin Oncol; 2017 May; 35(15):1730-1736. PubMed ID: 28339328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of leucocyte DNA thioguanine nucleotide levels during maintenance therapy of childhood acute lymphoblastic leukemia.
    Larsen RH; Hjalgrim LL; Degn M; Nersting J; Als-Nielsen B; Grell K; Schmiegelow K
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):53-60. PubMed ID: 33754188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia.
    Lancaster DL; Patel N; Lennard L; Lilleyman JS
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):33-6. PubMed ID: 12111109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.
    Stork LC; Matloub Y; Broxson E; La M; Yanofsky R; Sather H; Hutchinson R; Heerema NA; Sorrell AD; Masterson M; Bleyer A; Gaynon PS
    Blood; 2010 Apr; 115(14):2740-8. PubMed ID: 20124218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia.
    Stoneham S; Lennard L; Coen P; Lilleyman J; Saha V
    Br J Haematol; 2003 Oct; 123(1):100-2. PubMed ID: 14510948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia.
    Escherich G; Richards S; Stork LC; Vora AJ;
    Leukemia; 2011 Jun; 25(6):953-9. PubMed ID: 21372841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study.
    Lowe ES; Kitchen BJ; Erdmann G; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Woods W; Franklin J; Widemann BC; Balis FM; Murphy RF; Adamson PC
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):199-205. PubMed ID: 11320662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites.
    Lennard L; Welch J; Lilleyman JS
    Br J Clin Pharmacol; 1996 Oct; 42(4):525-7. PubMed ID: 8904630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
    Toksvang LN; Als-Nielsen B; Bacon C; Bertasiute R; Duarte X; Escherich G; Helgadottir EA; Johannsdottir IR; Jónsson ÓG; Kozlowski P; Langenskjöld C; Lepik K; Niinimäki R; Overgaard UM; Punab M; Räty R; Segers H; van der Sluis I; Smith OP; Strullu M; Vaitkevičienė G; Wik HS; Heyman M; Schmiegelow K
    BMC Cancer; 2022 May; 22(1):483. PubMed ID: 35501736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
    Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
    Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia.
    Larsen RH; Utke Rank C; Grell K; Nørgaard Møller L; Malthe Overgaard U; Kampmann P; Nersting J; Degn M; Nygaard Nielsen S; Holst H; Klug Albertsen B; Skov Wehner P; Thude Callesen M; Kanerva J; Leth Frandsen T; Als-Nielsen B; Lyngsie Hjalgrim L; Schmiegelow K
    Haematologica; 2021 Nov; 106(11):2824-2833. PubMed ID: 34047177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.